Carole Mitnick, ScD
About Carole Mitnick, ScD
Carole Mitnick, ScD received both her ScM and ScD in International Health Epidemiology and Ecology from the Harvard School of Public Health in Boston. She began working with Partners In Health in 1996 when she was a Fellow in Health and Social Justice. Dr. Mitnick was appointed an Instructor in the Department of Global Health and Social Medicine at Harvard Medical School in 2002. Her primary research centers on clinical outcomes research on multidrug-resistant tuberculosis (MDR-TB), particularly in resource-poor communities. Dr. Mitnick's current projects involve evaluating treatment protocols using novel analytic approaches and performing clinical trials of MDR-TB. She is also working to identify surrogate endpoints for MDR-TB therapy and to assess the effect of quality improvement initiatives on TB treatment outcomes.
(Source: http://www.brighamandwomens.org/socialmedicine/mitnickbio.aspx - photo credit: ©Suzanne Camarata Photography)
Role(s) / Profession(s)
- Researcher
Organization
- Brigham and Women's Hospital, Division of Global Health Equity
- Harvard Medical School, Department of Global Health and Social Medicine
- Partners In Health - PIH
Work Location(s)
- United States
Carole's Communities
Language(s)
- English
- French
- Spanish
Recent Contributions
-

Carole Mitnick, ScD replied to "Question about treatment outcome" in the MDR-TB Treatment & Prevention community.
Thanks, all. I agree with the discussion overall and the importance of separating the guidelines on clinical decision-making from those on reporting. This was one of the questions that proved most challenging when we first were working on the consensus definitions. We tried to come up with different scenarios depending on when the interruption occurred (first or second year) and on culture/smear status at reinitiation. Ultimately, I think the decision was that there were no ...
-

Carole Mitnick, ScD replied to "Cross-Post: Turning off the spigot: reducing drug-resistant tuberculosis transmission in resource-limited settings" in the MDR-TB Treatment & Prevention community.
Dear colleagues, Thank you to those who shared their thoughts so far. I would like to encourage everyone to share what method they use/have used in their setting for patient monitoring and support: community health workers, paper-based/coupons, or SMS for example, as this is a critical component of MDR-TB management. I have also found the following information on this topic and wonder: has anyone in the community experience with any of these methods for patient ...
-

Carole Mitnick, ScD replied to "Questions about Sputum Conversion for MDR-TB Patients" in the MDR-TB Treatment & Prevention community.
Michelle- I agree with Irina's comments below. Regarding the specific patient you mention in your response, i don't think there is any specific guidance offered in the Guidelines or in Laserson et al, IJTLD, 2005. These were both written under the assumption that sputum samples wouldn't be collected at the frequency at which you're collecting them. I guess, since the definitions are silent on any minimum interval between the baseline positive smear/culture and the first ...
Recent Recommendations
- None at this time.
